Biggest News Aggregation in the World
📰 Leukemia News

Page 173 - Leukemia News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.

Servier submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO (ivosidenib tablets) for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma

- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme - TIBSOVO is the first IDH1 mutation specific targeted therapy submitted in Europe - The submission
France General Prnewswire Servier Kostenloser Wertpapierhandel Claude Bertrand Philippe Gonnard European Union

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

Gregory Berk, M.D., the Companys President of R&D and Chief Medical Officer noted, "This pre-clinical evidence suggests, despite the difference in circulating immune cells of Stage IVB NSCLC patients, a mesothelin-targeted TriKE can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid
Jeff Miller Gregory Berk Anticancer Therapies Congress University Of Minnesota Gt Biopharma Inc Chief Medical Officer

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Researchers examine how structural violence can set the stage for poorer leukemia outcomes

Black and Hispanic people with acute myeloid leukemia in greater Chicago were more likely to die from the disease than their non-Hispanic white counterparts, with a 59% and 25% greater risk, respectively, according to a new study led by University of Illinois Chicago researchers.
United States University Of Illinois College Medicine Irum Khan Garth Rauscher Emily Henderson University Of Illinois Chicago

World Trade Center responders have increased levels of mutations that escalate blood cancer risk

Scientists from Vanderbilt-Ingram Cancer Center (VICC) collaborated with researchers from New York to determine that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease, according to a study published March 7 in Nature Medicine.
New York United States Memorial Sloan Kettering Cancer Center New York University Shannon Stockton Alexander Silver

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science